The clinical study reveals that the reduced blood glucose and elevated risk of hypoglycemia are present in LQT2 patients because of increased secretion of GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide) and insulin, as well as lowered glucagon secretion, which is resulting from loss-of-function mutations in hERG channels (Hyltén-Cavallius et al., 2017). The gene discussed is GIP; the disease is Hypoglycemia.